340 Phase 1 study of AMG 160, a half-life extended BiTE® (bispecific T-cell engager) therapy targeting prostate-specific membrane antigen, in patients with metastatic castration-resistant prostate cancer

• Ben Tran,
• Nabil Adra,
• Jean-Pascal Machiels,
• Sylvie Rottey,
• Tanya Dorff,
• Lisa Horvath,
• Matthew Rettig,
• Martijn Lolkema,
• Karen Autio,
• Richard Greil,
• Shirley Poon,
• Daniel Tan,
• Gabor Jurida,
• Hosein Kouros-Mehr

Affiliations

Ben Tran

12Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia

Nabil Adra

8Indiana University School of Medicine, Indianapolis, IN, United States

Jean-Pascal Machiels

Aff1 0000 0001 2294 713Xgrid.7942.8Department of Medical OncologyInstitut Roi Albert II, Cliniques universitaires Saint-Luc and Institut de Recherche Clinique et Expérimentale, Université catholique de Louvain Brussels Belgium

Sylvie Rottey

Aff3 0000 0004 0626 3303grid.410566.0Drug Research Unit GhentGhent University Hospital Ghent Belgium

Tanya Dorff

Aff1 0000 0004 0421 8357grid.410425.6Department of Medical Oncology & Experimental TherapeuticsCity of Hope Comprehensive Cancer Center 1500 East Duarte Road 91010 Duarte CA USA

Lisa Horvath

14 Chris O’Brien Lifehouse, Sydney, New South Wales, Australia

Matthew Rettig

2UCLA, Los Angeles, CA, United States

Martijn Lolkema

4Erasmus MC Cancer Institute, Rotterdam, Netherlands

Karen Autio

4Erasmus MC Cancer Institute, Rotterdam, Netherlands

Richard Greil

6IIIrd Medical Department, Paracelsus Me, Salzburg, Austria

Shirley Poon

9Amgen Inc, Thousand Oaks, CA, United States

Daniel Tan

10National Cancer Centre Singapore, Singapore, Singapore

Gabor Jurida

9Amgen Inc, Thousand Oaks, CA, United States

Hosein Kouros-Mehr

9Amgen Inc, Thousand Oaks, CA, United States